The Cardiovascular Group’s main office
is conveniently located on Atherholt Rd.
in Lynchburg, VA. We also have two
Satellite Clinics in Bedford and Gretna which primarily provide the following
services:
The Cardiovascular Group
P.O. Box 11709
Lynchburg, VA 24501-1709
New approaches in the diagnosis, prevention, and treatment of heart disease occur as a result of clinical trials. The specialized research staff of The Cardiovascular Group and Centra-Stroobants Heart Center is dedicated to performing clinical trials safely and efficiently, while simultaneously addressing the individual needs of each research study patient. Special care is taken to help patients understand the study so that they can be active participants in their treatment. All patient information regarding clinical trials is kept confidential.
Individuals participating in a clinical trial must meet certain requirements, such as physical condition, age, or stage of disease and must be willing to sign a consent form. Consent must be given freely without influence to participate in a study after being informed of the purpose, procedures, risks, and benefits.
Our commitment is to be on the cutting-edge of cardiovascular care through the introduction of promising new methods of treatments and participation in clinical research. Our research projects are at least nationwide and most are worldwide efforts.
Click on the titles and expand for more information & viewing options.
Atrial fibrillation and risk of stroke - the serious side to having a heart that flutters...
Have you or someone you know been diagnosed with an irregular
heartbeat, also known as atrial fibrillation (Afib)?
A clinical research study now underway is looking for
volunteers.
A clinical research study is evaluating a new investigational blood-thinning medication designed to reduce the risk of blood clot formation that can lead to stroke. You may be eligible to participate if you have been diagnosed with Afib and you:
Have had a prior stroke, transient ischemic attack or other
type of blood clot originating in the heart or:
Have two or more of the following risk factors:
age greater than or equal to 75 years
high blood pressure
heart failure signs and symptoms
diabetes mellitus
Study participants will receive study medications and related medical care at no cost. Compensation may be provided for study-related travel.
To find out more, without any obligation, contact your cardiologist.
Sponsored by NIH and University of Toledo. This study is for patients with a blockage in a kidney artery and high blood pressure that is difficult to control on 2 or more anti-hypertensive medications. 1080 patients will be randomized (like the flip of a coin), with half receiving a stent to the kidney artery along with medical therapy and half receiving medical therapy without a stent. Patients are followed with office visits for the study for up to 5 years. Some medications are provided for free by the study.
Contact Joyce White, NP at jwhitpps@aol.com for more information. Dr. Daniel Carey is the Principle Investigator.
This study is taking place at Lynchburg General Hospital and is for patients with blockages of their coronary (heart) arteries who are receiving a stent in the cath lab. The study is sponsored by The Medicines Company, the maker of the research drug, Cangrelor. Cangrelor inactivates the platelets in the blood and decreases the risk of inappropriate blood clots. Patients are reandomized (like a toss of a coin), at the time of their stent procedure to Cangrelor in the vein or plavix by mouth. All patients then will take daily Plavix for a time specified by their cardiologist. Study follow up lasts for one year and is done by phone contact.
Contact Joyce White, NP at jwhitpps@aol.com for more information. Dr. Thomas Nygaard is the Principle Investigator.
This study is sponsored by Schering-Plough, the maker of integrilin, a drug that decreases the ability of the blood platelets to cause a clot. This study is for patients who are hospitalized with angina (pain from the heart) or a small heart attack. Patients are randomized (like the toss of a coin) to recerive integrilin or placebo at least 12 hours before they have a heart catheterization. Most patients now receive a drug like integrilin in the cath lab if they get a stent. This study is trying to show if patients will do better when they get the drug at least 12 hours before a stent.
Contact Joyce White, NP at jwhitpps@aol.com for more information. Dr. Thomas Nygaard is the Principle Investigator.
This study is sponsored by Schering-Plough, the maker of Zocor and Vytorin, two drugs that decrease cholesterol. This study is only for patients who have been hospitalized with angina (pain from the heart) or a heart attack. Patients must be randomized (like the toss of a coin) within 10 days of the start of their hospitalization. They receive Zocor or Vytorin, which is provided by the sponsor. Blood work to check cholesterol is done at each study visit and is free. Patients are followed for study visits for 2.5 to 4 years.
Contact Joyce White, NP at jwhitpps@aol.com for more information. Dr. Thomas Nygaard is the Principle Investigator.
Click on the titles and expand for more information & viewing options. 
